Elevance Health (NYSE:ELV) 株価情報

Elevance Health

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Elevance Health Inc

Electrovaya Inc

Evolva Holding SA

Evolva Holding SA ADR

ELVICTOR GROUP INC by Elvictor Group, Inc

Elvictor Group Inc

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

ELEVATE URANIUM LTD by Elevate Uranium Ltd.

Elevate Uranium Ltd

EVOLVA HLDG AG S/ADR by Evolva Holding AG

Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) is in the spotlight ahead earnings Tuesday. Here&#8217;s what you <a href="https://www.benzinga.com//node/45046664">need to know.</a>
What To Know: Analysts&#8217; estimate first-quarter earnings of 3 cents per share and revenue of $1.35 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
The company previously guided for revenue between $1.23 billion and $1.36 billion and adjusted EBITDA between $40 million and $75 million for the first-quarter.
Snap also expects infrastructure costs per daily active user to be between 82 cents and 87 cents. Content, developer, advertising partner and other costs are expected to represent 19% to 20% of revenue.
In its last letter to shareholders, the company said, &#8220;As we look ahead to 2025, we see additional opportunities to invest productively in scaling our business given the foundational improvements we have made to our ad platform and the momentum we have established in our go to market initiatives, particularly the SMB segment. Our investment plans for 2025 reflect this optimism, alongside a strong commitment to make further financial progress towards profitability as we scale.&#8221;
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45067585/amazon-stock-tumbles-as-white-house-calls-tariff-visibility-plans-a-hostile-act">Amazon Stock Tumbles As White House Calls Tariff Visibility Plans A &#8216;Hostile&#8217; Act</a>
SNAP Price Action: At the time of writing, Snap stock is trading 1.0.8% higher at $8.92, per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image: via Shutterstock

News

Movers

SNAP

What's Going On With Snap Stock Tuesday?

UBS analyst Timothy Arcuri maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Neutral and lowers the price target from $70 to $65.

Price Target

Analyst Ratings

SWKS

UBS Maintains Neutral on Skyworks Solutions, Lowers Price Target to $65

UBS analyst John Nadel maintains Principal Financial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Neutral and lowers the price target from $93 to $80.

UBS Maintains Neutral on Principal Financial Group, Lowers Price Target to $80

UBS analyst Pradeep Ramani maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and lowers the price target from $55 to $40.

UBS Maintains Neutral on ON Semiconductor, Lowers Price Target to $40

WIIM

Wells Fargo shares are trading higher after the company's board authorized a $40 billion stock repurchase program.

UBS analyst Kunal Madhukar maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $34 to $31.

MTCH

UBS Maintains Neutral on Match Group, Lowers Price Target to $31

Correction: Guggenheim analyst Michael Schmidt downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $77 to $47. (Analyst Firm change from Stephens &amp; Co. to Guggenheim)

Downgrades

SWTX

Correction: Guggenheim Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47 (Firm change from Stephens & Co. to Guggenheim)

BMO Capital analyst Michael Zaremski maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Outperform and raises the price target from $92 to $96.

SIGI

BMO Capital Maintains Outperform on Selective Insurance Gr, Raises Price Target to $96

UBS analyst Taylor McGinnis maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Neutral and lowers the price target from $350 to $310.

MNDY

UBS Maintains Neutral on Monday.Com, Lowers Price Target to $310

BMO Capital analyst Ari Klein maintains SBA Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Market Perform and raises the price target from $230 to $240.

SBAC

BMO Capital Maintains Market Perform on SBA Communications, Raises Price Target to $240

UBS analyst Pradeep Ramani maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $70 to $55.

MCHP

UBS Maintains Buy on Microchip Technology, Lowers Price Target to $55

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 20 years by 8.88% on an annualized basis producing an average annual return of 16.92%. Currently, AZZ has a market capitalization of $2.57 billion. 
Buying $1000 In AZZ: If an investor had bought $1000 of AZZ stock 20 years ago, it would be worth $22,594.59 today based on a price of $86.00 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745937911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

BMO Capital analyst Andrew Strelzik maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and raises the price target from $515 to $540.

BMO Capital Maintains Outperform on Domino's Pizza, Raises Price Target to $540

UBS analyst Danielle Antalffy maintains InMode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Neutral and lowers the price target from $19 to $16.25.

INMD

UBS Maintains Neutral on InMode, Lowers Price Target to $16.25

BMO Capital analyst James Thalacker maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Outperform and raises the price target from $77 to $79.

BMO Capital Maintains Outperform on CMS Energy, Raises Price Target to $79

UBS analyst Timothy Arcuri maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $37.

UBS Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $37

Piper Sandler analyst James Fish maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Neutral and raises the price target from $262 to $269.

FFIV

Piper Sandler Maintains Neutral on F5, Raises Price Target to $269

UBS analyst Timothy Arcuri maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral and lowers the price target from $115 to $90.

ENTG

UBS Maintains Neutral on Entegris, Lowers Price Target to $90

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Overweight and raises the price target from $90 to $105.

Reiteration

TMDX

Piper Sandler Reiterates Overweight on TransMedics Group, Raises Price Target to $105

UBS analyst Timothy Arcuri maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $215 to $165.

UBS Maintains Buy on ARM Holdings, Lowers Price Target to $165

Legal

Press Releases

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Elevance Health, Inc. Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

AM Best Affirms Credit Ratings of Elevance Health, Inc. and Its Subsidiaries

Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders

Comments

Elevance Health

ニュース

パートナーシップ

ベンジンガ・グローバル